Suppr超能文献

评价针对疟原虫和 vivax 疟原虫传播的联合疫苗。

Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.

机构信息

Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington D.C., USA.

Plataforma de Produção e Infecção de Vetores da Malária, Laboratório de Entomologia - FIOCRUZ RO, Rua da Beira 7671, CEP 76812-245 Porto Velho RO, Brazil; Programa de Pós-Graduação em Saúde Pública, Faculdade de Saúde Pública, Universidade Federal de São Paulo, São Paulo 01246-904, SP, Brazil.

出版信息

Vaccine. 2024 Aug 30;42(21):126140. doi: 10.1016/j.vaccine.2024.07.041. Epub 2024 Jul 20.

Abstract

Transmission-blocking vaccines interrupting malaria transmission within mosquitoes represent an ideal public health tool to eliminate malaria at the population level. Plasmodium falciparum and P. vivax account for more than 90% of the global malaria burden, co-endemic in many regions of the world. P25 and P48/45 are two leading candidates for both species and have shown promising transmission-blocking activity in preclinical and clinical studies. However, neither of these target antigens as individual vaccines has induced complete transmission inhibition in mosquitoes. In this study, we assessed immunogenicity of combination vaccines based on P25 and P48/45 using a DNA vaccine platform to broaden vaccine specificity against P. falciparum and P. vivax. Individual DNA vaccines encoding Pvs25, Pfs25, Pvs48/45 and Pfs48/45, as well as various combinations including (Pvs25 + Pvs48/45), (Pfs25 + Pfs48/45), (Pvs25 + Pfs25), and (Pvs48/45 + Pfs48/45), were evaluated in mice using in vivo electroporation. Potent antibody responses were induced in mice immunized with individual and combination DNA vaccines, and specific antibody responses were not compromised when combinations of DNA vaccines were evaluated against individual DNA vaccines. The anti-Pvs25 IgG from individual and combination groups revealed concentration-dependent transmission-reducing activity (TRA) in direct membrane feeding assays (DMFA) using blood from P. vivax-infected donors in Brazil and independently in ex vivo MFA using Pvs25-transgenic P. berghei. Similarly, anti-Pfs25 and anti-Pfs48/45 IgGs from mice immunized with Pfs25 and Pfs48/45 DNA vaccines individually and in various combinations revealed antibody dose-dependent TRA in standard membrane feeding assays (SMFA) using culture-derived P. falciparum gametocytes. However, antibodies induced by immunization with Pvs48/45 DNA vaccines were ineffective in DMFA and require further vaccine construct optimization, considering the possibility of induction of both transmission-blocking and transmission-enhancing antibodies revealed by competition ELISA. These studies provide a rationale for combining multiple antigens to simultaneously target transmission of malaria caused by P. falciparum and P. vivax.

摘要

阻断疟疾在蚊子中的传播的疫苗可以在人群层面上消灭疟疾,这是一种理想的公共卫生工具。恶性疟原虫和间日疟原虫占全球疟疾负担的 90%以上,在世界许多地区同时流行。P25 和 P48/45 是这两种寄生虫的主要候选疫苗,在临床前和临床研究中均表现出有希望的阻断传播活性。然而,作为单一疫苗,这两种靶抗原都没有在蚊子中完全抑制传播。在这项研究中,我们使用 DNA 疫苗平台评估了基于 P25 和 P48/45 的联合疫苗的免疫原性,以扩大针对恶性疟原虫和间日疟原虫的疫苗特异性。单独的 DNA 疫苗编码 Pvs25、Pfs25、Pvs48/45 和 Pfs48/45,以及包括(Pvs25 + Pvs48/45)、(Pfs25 + Pfs48/45)、(Pvs25 + Pfs25)和(Pvs48/45 + Pfs48/45)在内的各种组合,均在使用体内电穿孔的小鼠中进行了评估。用单独和联合 DNA 疫苗免疫的小鼠均诱导出有效的抗体应答,并且当评估 DNA 疫苗组合与单独 DNA 疫苗时,特异性抗体应答不受影响。来自个体和组合组的抗 Pvs25 IgG 在直接膜喂养试验(DMFA)中显示出浓度依赖性的传播减少活性(TRA),使用来自巴西感染间日疟原虫的供体的血液,并在使用 Pvs25 转基因伯氏疟原虫的离体 MFA 中独立地显示出 TRA。同样,用 Pfs25 和 Pfs48/45 DNA 疫苗单独和组合免疫的小鼠产生的抗 Pfs25 和抗 Pfs48/45 IgG 在使用培养衍生的恶性疟原虫配子体的标准膜喂养试验(SMFA)中显示出抗体剂量依赖性的 TRA。然而,用 Pvs48/45 DNA 疫苗免疫诱导的抗体在 DMFA 中无效,需要进一步优化疫苗构建,因为竞争 ELISA 显示出可能诱导传播阻断和增强抗体。这些研究为同时针对恶性疟原虫和间日疟原虫引起的疟疾传播提供了联合多种抗原的原理。

相似文献

1
Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
Vaccine. 2024 Aug 30;42(21):126140. doi: 10.1016/j.vaccine.2024.07.041. Epub 2024 Jul 20.
3
Advances in transmission-blocking vaccines against and .
Expert Rev Vaccines. 2025 Dec;24(1):509-523. doi: 10.1080/14760584.2025.2517720. Epub 2025 Jun 18.
4
Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
Vaccine. 2015 Apr 15;33(16):1901-8. doi: 10.1016/j.vaccine.2015.03.008. Epub 2015 Mar 10.

引用本文的文献

本文引用的文献

1
Immune mechanisms targeting malaria transmission: opportunities for vaccine development.
Expert Rev Vaccines. 2024 Jan-Dec;23(1):645-654. doi: 10.1080/14760584.2024.2369583. Epub 2024 Jun 25.
3
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1.
4
Transmission-reducing and -enhancing monoclonal antibodies against gamete surface protein Pvs48/45.
Infect Immun. 2024 Mar 12;92(3):e0037423. doi: 10.1128/iai.00374-23. Epub 2024 Jan 30.
6
A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax.
NPJ Vaccines. 2023 Dec 14;8(1):187. doi: 10.1038/s41541-023-00786-9.
7
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
Lancet Infect Dis. 2023 Nov;23(11):1266-1279. doi: 10.1016/S1473-3099(23)00276-1. Epub 2023 Jul 24.
8
Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission.
iScience. 2023 Jun 22;26(7):107192. doi: 10.1016/j.isci.2023.107192. eCollection 2023 Jul 21.
10
Co-infection of the four major Plasmodium species: Effects on densities and gametocyte carriage.
PLoS Negl Trop Dis. 2022 Sep 13;16(9):e0010760. doi: 10.1371/journal.pntd.0010760. eCollection 2022 Sep.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验